undamentalytics Newsletter

Codexis, Inc. balance sheet

At the end of fiscal 2025, Codexis, Inc. had total assets of $148m, total liabilities of $97.3m and shareholders' equity of $50.5m. It held $50.8m in cash against $42.2m of debt: net cash of $8.6m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Codexis, Inc.: balance sheet, annual
Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents327226322226231931539014911711465195127
Receivables—1519854761112914253210191112
Inventory—34111111101123222
Total current assets—92796036333327456811418416216393999772
Goodwill—33333333333332222
Total assets—141136100594845365479149222246250137149148120
Accounts payable—910445344333336323
Deferred revenue (current)—5422362125023510071
Total current liabilities—2728161114151225181525334936242524
Short-term debt————————————————07
Long-term debt———————00—————0294034
Total debt000000000000000324242
Total liabilities————17—2217292344528210650829787
Shareholders' equity−1451071037841262319255610617016414587675133
Net debt (negative = net cash)−32−72−26−32−22−26−23−19−31−53−90−149−117−114−6513−915
Shares outstanding——36m38m38m40m40m41m48m54m59m64m65m66m70m82m90m91m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BNR vs CDXSCDXS vs XGNCDXS vs PSNLCDXS vs HBIO

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Codexis, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Codexis, Inc.